WO2005018563A3 - Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury - Google Patents

Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury Download PDF

Info

Publication number
WO2005018563A3
WO2005018563A3 PCT/US2004/027146 US2004027146W WO2005018563A3 WO 2005018563 A3 WO2005018563 A3 WO 2005018563A3 US 2004027146 W US2004027146 W US 2004027146W WO 2005018563 A3 WO2005018563 A3 WO 2005018563A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
nervous system
central nervous
inhibitor
cyclooxygenase
Prior art date
Application number
PCT/US2004/027146
Other languages
French (fr)
Other versions
WO2005018563A2 (en
Inventor
Diane T Stephenson
Original Assignee
Pharmacia Corp
Diane T Stephenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Diane T Stephenson filed Critical Pharmacia Corp
Publication of WO2005018563A2 publication Critical patent/WO2005018563A2/en
Publication of WO2005018563A3 publication Critical patent/WO2005018563A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings

Abstract

The present invention provides compositions and methods for the treatment of central nervous system disorders. In some aspects, the invention provides a combination therapy for the treatment of a central nervous system ischemic mediated disorder comprising the administration to a subject of a PDE inhibitor in combination with a cyclooxygenase-2 selective inhibitor.
PCT/US2004/027146 2003-08-22 2004-08-20 Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury WO2005018563A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49730503P 2003-08-22 2003-08-22
US60/497,305 2003-08-22

Publications (2)

Publication Number Publication Date
WO2005018563A2 WO2005018563A2 (en) 2005-03-03
WO2005018563A3 true WO2005018563A3 (en) 2005-12-29

Family

ID=34216109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/027146 WO2005018563A2 (en) 2003-08-22 2004-08-20 Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury

Country Status (2)

Country Link
US (1) US20050130971A1 (en)
WO (1) WO2005018563A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010450A (en) * 2007-03-27 2009-11-23 Omeros Corp The use of pde7 inhibitors for the treatment of movement disorders.
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5932598A (en) * 1996-04-12 1999-08-03 G. D. Searle & Co. Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6291523B1 (en) * 1997-08-28 2001-09-18 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
US20030069169A1 (en) * 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK167878B1 (en) * 1985-04-19 1993-12-27 Sankyo Co PIGEOLIC ACID DERIVATIVES
TW201305B (en) * 1991-04-03 1993-03-01 Otsuka Pharma Co Ltd
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
AU755350B2 (en) * 1997-08-06 2002-12-12 Daiichi Asubio Pharma Co., Ltd. 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase nhibitor
US20020048599A1 (en) * 2000-10-20 2002-04-25 Thomas H. Mueller Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5932598A (en) * 1996-04-12 1999-08-03 G. D. Searle & Co. Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6291523B1 (en) * 1997-08-28 2001-09-18 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
US20030069169A1 (en) * 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

Also Published As

Publication number Publication date
US20050130971A1 (en) 2005-06-16
WO2005018563A2 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2004093814A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
HK1088895A1 (en)
WO2004009590A8 (en) 4-amino-substituted pyrimidine derivatives
WO2006072828A3 (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
HK1087351A1 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
WO2003015608A3 (en) Combination therapy for the treatment of cancer
IL170710A0 (en) Selective cytokine inhibitory drugs for treating disorders of the central nervous system
WO2005023189A3 (en) Method of cox-2 selective inhibitor and nitric oxide-donating agent
IL177861A0 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2004052404A3 (en) Glycogen synthase kinase-3 inhibitors
WO2005000192A3 (en) Glycogen synthase kinase-3 inhibitors
WO2005016249A3 (en) Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2007013962A3 (en) Rapid onset and short term modafinil compositions and methods of use thereof
WO2007026254A3 (en) Benzodiazepine derivatives , their preparation and the therapeutic use thereof
WO2005018563A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
WO2004105699A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
WO2005018541A3 (en) Cox-2 inhibitor and serotonin modulator for treating cns damage
WO2005020910A3 (en) Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
WO2010110646A8 (en) Aurones as selective pde inhibitors and their use in neurological conditions and disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase